According to their Press Release, The National Institutes of Health (NIH) awarded Chlamydia researchers at The South Texas Center for Emerging Infectious Diseases (STCEID) at The University of Texas at San Antonio (UTSA) a $1.8 million grant over the next five years to study the pathogenesis of Chlamydia trachomatis, the bacterium that causes human genital Chlamydia.
By studying this sexually transmitted disease, UTSA can better serve the pharmaceutical industry and work together to eradicate Chlamydia from the world's population.
Do you think this was a proper use of NIH funds? What other research are you seeing in this arena?
Search This Blog
Blog Archive
-
▼
2009
(141)
-
▼
February
(16)
- February Edition of Partnerships with CROs LinkedI...
- Unethical Clinical Trial Outsourcing
- New regulations from the Indian government
- Raising alarms, study sees trials migrating abroad
- Is Outsourcing of Clinical Trials Faulty?
- How to rescue a clinical trial
- Pfizer Plans to Disclose Payments Made to Clinical...
- Quintiles opens up Phase I Unit in India
- Microdosing could be a win/win for pharma, CROs
- PPD Extends its Reach to Eastern and Central Europe
- NIH Awards University of Texas $1.8M in Research G...
- Covance Opens Offices in Ukraine, Slovakia and Israel
- Covance expands into Eastern Europe and Middle East
- India to Conduct 5% Global Clinical Trials by 2012
- Executives are on the Move in the Outsourcing Indu...
- PRA International expands into southwest Asia
-
▼
February
(16)
No comments:
Post a Comment